8-K/A: Shattuck Labs Reports Q3 2025 Results, SL-325 Progress

Shattuck Labs announced third quarter 2025 financial results, highlighted by the dosing of first participants in its SL-325 Phase 1 trial and a private placement securing funding into 2029.

Summary

• Shattuck Labs reported a net loss of $10.1 million for the third quarter ended September 30, 2025, an improvement from a net loss of $16.6 million in the same period of 2024.
• Research and Development (R&D) expenses significantly decreased to $7.6 million in Q3 2025 from $16.3 million in Q3 2024.
• General and Administrative (G&A) expenses also saw a reduction, falling to $4.1 million in Q3 2025 from $4.6 million in Q3 2024.
• The company closed a private placement in August 2025, raising up to approximately $103 million, which is expected to fund operations into 2029, assuming full exercise of common stock warrants.
• First participants were dosed in the single-ascending dose (SAD) portion of the Phase 1 clinical trial for SL-325, a DR3 blocking antibody for inflammatory and immune-mediated diseases, in Q3 2025.
• Dan Baker, M.D., and Mona Ashiya, Ph.D., were appointed to Shattuck's Board of Directors in August 2025.

Sentiment

Score: 8

Explanation: The filing indicates strong positive momentum with significant clinical progress (SL-325 entering Phase 1), substantial capital secured extending the cash runway for several years, and improved financial efficiency with reduced net loss and operating expenses. The board appointments also add to positive governance. The primary caution is the dilution from the capital raise and the inherent risks of clinical development.

Positives

• Net loss significantly improved to $10.1 million in Q3 2025 from $16.6 million in Q3 2024.
• R&D expenses decreased by over 50% year-over-year, from $16.3 million to $7.6 million, indicating more efficient resource allocation or completion of certain development phases.
• Successful completion of a private placement raising up to $103 million, extending the company's cash runway into 2029, assuming full warrant exercise.
• Initiation of the Phase 1 clinical trial for SL-325, marking its entry into clinical development as a potentially first-in-class DR3 blocking antibody.
• Appointments of two experienced professionals, Dan Baker, M.D., and Mona Ashiya, Ph.D., to the Board of Directors, strengthening corporate governance and expertise.

Negatives

• Cash and cash equivalents and short-term investments decreased slightly to $86.1 million as of September 30, 2025, compared to $90.1 million as of September 30, 2024, prior to the full impact of the private placement warrants.
• Weighted-average shares outstanding increased significantly to 72,184,818 in Q3 2025 from 50,833,538 in Q3 2024, indicating dilution from the private placement.

Risks

• Global macroeconomic conditions and related volatility could impact operations and financial performance.
• Uncertainty regarding the expected results of preclinical studies, clinical trials, and research and development programs.
• Risks associated with the timing, completion, and outcome of clinical trials, including the unpredictable relationship between preclinical study results and clinical study results.
• Uncertainty regarding the timing or likelihood of regulatory filings and approvals for product candidates.
• Liquidity and capital resources, including whether the common stock warrants issued in the private placement will be fully exercised and provide the company with additional capital.
• Other risks and uncertainties identified in Shattuck's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent SEC filings.

Future Outlook

Shattuck Labs expects to complete enrollment for both single-ascending dose (SAD) and multiple-ascending dose (MAD) portions of the SL-325 Phase 1 clinical trial by the second quarter of 2026, with initial results anticipated by the same quarter. The company plans to advance SL-325 into Phase 2 trials for IBD and potentially other autoimmune diseases. Additionally, Shattuck aims to announce a lead bispecific candidate from its preclinical pipeline in the first half of 2026. The company's current capital resources, assuming full exercise of outstanding common stock warrants, are projected to fund operations into 2029.

Management Comments

• "In the third quarter of 2025, SL-325 became the first DR3 blocking antibody to enter clinical development, and our Phase 1 trial is proceeding as we anticipated."
• "With the successful closing of our private placement, and assuming the full exercise of the common stock warrants issued in the private placement, we are well-capitalized to advance SL-325 into Phase 2 trials."
• "We are executing with discipline and remain focused on generating data that supports SL-325 as a potentially first-in-class DR3 blocking antibody."

Industry Context

Shattuck Labs operates in the highly competitive biotechnology sector, specifically focusing on novel therapeutics for inflammatory and immune-mediated diseases by targeting TNF superfamily receptors. The advancement of SL-325 as a potentially first-in-class DR3 blocking antibody positions the company in a niche but potentially high-impact area, particularly for conditions like Inflammatory Bowel Disease (IBD). The successful initiation of a Phase 1 trial and securing significant funding are critical milestones in this capital-intensive industry, signaling progress and investor confidence in its unique approach compared to more common TL1A antibody strategies.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct assessment against global benchmarks. However, the company highlights SL-325 as a "potentially first-in-class DR3 antagonist antibody," suggesting a novel mechanism of action compared to existing or developing treatments for IBD and autoimmune diseases.
• Shattuck's preclinical studies for SL-325 are noted to demonstrate "high affinity binding and superior activity over TL1A antibodies," indicating a differentiated approach within the inflammatory disease therapeutic landscape, where TL1A is also a target.

Management Changes

Stakeholder Impact

• Shareholders: Potential for future value creation through clinical progress of SL-325 and extended cash runway, but also dilution from the recent private placement.
• Employees: Continued stability and focus on key development programs due to extended funding.
• Patients: Progress towards potential new therapeutic options for inflammatory and immune-mediated diseases, particularly IBD, with SL-325 entering clinical trials.
• Creditors: Improved financial stability and reduced short-term liquidity concerns due to the capital raise.

Next Steps

• Complete enrollment of SAD and MAD portions of the SL-325 Phase 1 clinical trial by the second quarter of 2026.
• Disclose initial safety, tolerability, DR3 occupancy, immunogenicity, and PK data from the SL-325 Phase 1 trial by the second quarter of 2026.
• Advance SL-325 into Phase 2 clinical trials for IBD and potentially other autoimmune diseases.
• Announce a lead bispecific candidate from the preclinical pipeline in the first half of 2026.
• Participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025.
• Participate in the Evercore ISI 8th Annual Healthcare Conference on December 3-4, 2025.

Key Dates

Recommendation

The filing presents several positive developments, including significant clinical progress with SL-325 entering Phase 1, a substantial capital raise extending the cash runway into 2029, and improved financial metrics with a reduced net loss. These factors suggest a positive trajectory for the company. However, the increase in weighted-average shares outstanding indicates dilution, and the inherent risks of clinical development in biotechnology remain. While the long-term outlook appears promising, a 'hold' recommendation is prudent until initial Phase 1 results are disclosed in Q2 2026, which will provide more concrete data on SL-325's safety and tolerability, allowing for a more informed assessment of its potential.

Keywords

Shattuck Labs, STTK, biotechnology, Q3 2025 earnings, financial results, SL-325, DR3 blocking antibody, Phase 1 clinical trial, inflammatory bowel disease, IBD, autoimmune diseases, private placement, cash runway, clinical development, TNF superfamily receptors